Several agonists for both receptors have been synthesized; for example, the ursodeoxycholic acid (UDCA), investigated in various randomized controlled trials, displayed only biochemical, but not histological benefits [37]; differently, the FXR agonist obeticholic acid (OCA) is now the prototype for this kind of compounds because of its positive effects on insulin resistance [153]. The gene discussed is NR1H4; the disease is Insulin resistance.